2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Omics Technologies, Bioinformatics, Cell Expansion, Computational Biology, Treatment Considerations, Drug Development, Biological Therapies, Transplantation, Gene Therapy, Adverse Events, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Genetic Disorders, Hemoglobinopathies, Sickle Cell Disease, Research, Fundamental Science, Translational Research, Clinical Research, Epidemiology, Study Population, Human, Adult, Pediatric, Animal Model
PAPER

1149 Mitapivat rapidly restores red blood cell membrane integrity: A window for pre-emptive intervention in sickle cell vaso-occlusive crisis

Swee Lay Thein, MD, DSc, Kang Le, PhD2, Jennifer Nwokeji3, Shruti Bhatt, PhD4, Shijinqiu Gao, MSc5, Anna Conrey6
1 National Heart, Lung and Blood Institutes / NIH, Bethesda, Maryland, United States
2 National Heart, Lung and Blood Institutes / NIH, Bethesda, Maryland, United States
3 National Heart, Lung and Blood Institutes / NIH, Bethesda, Maryland, United States
4 National Heart, Lung and Blood Institutes / NIH, Bethesda, Maryland, United States
5 National Heart, Lung and Blood Institutes / NIH, Bethesda, Maryland, United States
6 National Heart, Lung and Blood Institutes / NIH, Bethesda, Maryland, United States

Sickle cell disease (SCD) affects an estimated 8 million people globally, including 100,000 in the US, with substantial morbidity and early mortality, Recurrent vaso-occlusive crises (VOCs) and episodes of acute pain, are the leading cause of SCD-related hospitalizations. VOCs are triggered by red blood cell (RBC) sickling and accompanied by acute-on-chronic hemolysis from a weakened RBC membrane, releasing damage-associated molecular patterns (DAMPs), inflammatory cytokines, and proadhesive factors that promote hypoxia and further sickling, a self-amplifying cycle that can rapidly escalate a prodrome into a full crisis. Most painful episodes lack an identifiable trigger, though patients often experience this prodromal phase. Current VOC management focuses on symptomatic relief once a crisis is established, leaving a critical gap in disease-modifying options that act during this early, potentially reversible window.

Extracellular vesicles (EVs) and free heme released upon membrane compromise are key drivers of VOC pathophysiology, making membrane restoration a mechanically justified target. Phosphorylation of band 3 tyrosine residues (Tyr8, Tyr21) weakens lipid bilayer-cytoskeleton attachment by disassociating ankyrin from band 3, causing blebbing, vesiculation and heme release. We previously showed that mitapivat, a pyruvate kinase activator, reduces tyrosine-phosphorylated band 3 (Tyr-p-bd3) by increasing intracellular ATP, improving membrane integrity and RBC lifespan, with reductions in Tyr-p-bd3 detectable ex vivo within 4 hours, raising the possibility of intervening before a prodrome progresses to crisis. Here we examine early biomarker changes in a dose-ascending mitapivat study and its potential for pre-emptive VOC intervention.

We analyzed frozen whole blood/plasma from the Phase 1 mitapivat Dose-Ascending Study (NCT04000165). Of 16 enrolled patients, evaluable samples from 12 were used to isolate RBC membranes at predose, 1, 2, 4, 8, and 12 hours post-dose (5 mg, 20 mg, 50 mg, and 100 mg); heme was measured in parallel (12-hour timepoints available for 4 of the 12 patients). Mean percentage change in Tyr-p-bd3 and heme from predose were calculated at timepoint/dose and tested against a null of 0% (two-sided one-sample t-tests). Separately, 9 paired frozen whole blood/plasma samples from HbSS patients in steady vs. crisis state (Acute Pain Study, NCT03049475) were analyzed for Tyr-p-bd3 (western blot) and heme. Crisis-to-steady-state ratios (null = 1) were tested using two-sided one-sample t-tests; Spearman correlation assessed association between percentage changes in each marker from steady state. Statistical significance was set at p<0.05. Ex vivo, HbSS RBCs were pretreated with mitapivat for 2 hours before hypoxia exposure, with supernatants collected at baseline, 2, 4, 8, and 10 hours post-hypoxia. EV concentration and heme were measured by nanoparticle tracking analysis and the QuantiChrom Heme Assay, respectively (mitapivat at 50 uM, 100 uM).

As of submission, Tyr-p-bd3 and plasma heme analyses were complete for 5 and 12 patients, respectively, in the Phase 1 Dose-Ascending Study. Mitapivat reduced mean Tyr-p-bd3 within 8 hours at all doses (within 4 hours at ≥20 mg) and reduced mean heme within 8 hours at all doses, with dose-and time-dependent effects for both markers. Tyr-p-bd3 and plasma heme were significantly higher during crisis than steady-state (p< 0.01 and p< 0.05, respectively), and percentage changes in the 2 markers at steady-state were positively correlated (Spearman rank correlation: ρ = 0.70, two-sided p = 0.0358; n = 9). Ex vivo, hypoxia dramatically increased EV and heme release over time, while mitapivat pretreatment largely blocked this release, with effects apparent by 2 hours post-hypoxia.

Compromised RBC membrane integrity and erythroid DAMP release represent the step most temporally proximal to the prodrome-to-crisis transition, making restoration of membrane integrity a mechanistically plausible strategy to interrupt triggering events during this window. Mitapivat rapidly improved membrane integrity both ex vivo and in vivo, with biomarker changes emerging within hours of dosing, a timescale that aligns with the brief prodromal period preceding most VOCs.  These findings position mitapivat as a candidate for pre-emptive, disease-modifying intervention within this narrow but clinically actionable therapeutic window, rather than for symptomatic relief after a crisis has begun.

Kang Le, PhD: No relevant conflicts of interest to declare.